Bias in AI: The 200 Million Patient Healthcare Disparity

The promise of artificial intelligence in healthcare is vast, offering unprecedented opportunities for efficiency, accuracy, and personalized medicine. Yet, as with any powerful technology, the risks of unchecked or poorly designed AI can be profound, leading to documented failures that undermine patient safety and exacerbate existing health disparities. One of the most stark examples of this critical vulnerability emerged from a 2019 study published in Science, which uncovered an algorithmic bias that systematically underestimated the healthcare needs of over 200 million Black patients.

The Algorithm’s Blind Spot: Cost as a Proxy for Health

The core of this alarming discovery revolved around a widely used algorithm developed by Optum, a subsidiary of UnitedHealth Group, designed to identify patients with complex health needs who would benefit most from care management programs. The algorithm’s fundamental flaw, as articulated by researchers including Ziad Obermeyer, who is currently the Blue Cross of California Distinguished Associate Professor at the UC Berkeley School of Public Health, was its reliance on healthcare costs as a proxy for health status. While seemingly logical on the surface, this design choice encoded a deep-seated societal inequity into the very fabric of the AI. The mechanism of bias was insidious: because Black patients in the United States have historically faced structural racism within the healthcare system, they often receive less care for the same level of illness compared to white patients. This results in lower healthcare costs, not because their health needs are less severe, but because they are underserved. When an algorithm uses past healthcare spending to predict future health needs, it inadvertently learns and perpetuates this disparity. Lower historical costs for Black patients were interpreted by the algorithm as lower health risk, even when their underlying medical conditions were identical to, or more severe than, those of white patients who incurred higher costs. The impact was devastatingly clear: the Optum algorithm recommended care management programs to Black patients at significantly lower rates than white patients, even when both groups presented with the same chronic conditions and objective severity of illness. Specifically, the study found that at equivalent risk scores generated by the algorithm, Black patients were nearly 50% less likely to be assigned to programs designed to improve health outcomes Original Science paper on algorithmic bias. This meant millions of Black patients were systematically undertriaged, missing out on crucial interventions that could prevent complications, reduce suffering, and save lives.

Unpacking the Disparity: 50%+ Care Reduction at Equal Risk Scores

The quantitative findings of the Science study are particularly damning for Patient Safety Advocates and underscore the critical importance of rigorous algorithmic fairness auditing for Investors and Regulatory Officers. The research demonstrated that for patients with the same level of illness, as measured by objective clinical indicators, the algorithm assigned Black patients lower risk scores than white patients. This discrepancy was not marginal; it translated into a tangible reduction in access to care. Imagine two patients, one Black and one white, both suffering from the same chronic heart condition, requiring similar levels of clinical attention. The Optum algorithm, driven by its cost-based proxy, would likely assign the Black patient a lower risk score, thereby reducing their chances of being flagged for proactive care management. The study revealed that if an algorithm aims to identify the top 10% highest-risk patients, for example, to allocate scarce resources, the threshold for Black patients would effectively be much higher than for white patients. This led to a staggering observation: for patients who were equally sick, Black patients received over 50% less care than their white counterparts as a direct consequence of the algorithm’s biased recommendations. This is not merely a theoretical issue; it represents a tangible failure in patient safety and health equity on a massive scale, impacting an estimated 200 million individuals across the United States.

A Call for Responsible AI: Obermeyer’s Corrective Framework and Clinically Validated Alternatives

The revelations from Obermeyer’s team at UC Berkeley School of Public Health, which included researchers from Princeton University, sparked a vital conversation about algorithmic bias and the urgent need for responsible AI development in healthcare. Sociologist Ruha Benjamin of Princeton University has extensively written on the societal implications of such technological biases, emphasizing how algorithms can perpetuate and even amplify existing inequalities. The study not only exposed the problem but also offered a corrective framework, demonstrating that by re-training the algorithm to predict future illness directly, rather than relying on cost as a proxy, the racial bias could be significantly reduced. This revised approach led to a substantial increase in the proportion of Black patients identified for extra care, correcting the historical under-allocation. This incident serves as a crucial case study for the FDA SaMD Framework and the FTC Algorithmic Fairness guidelines, highlighting the imperative for pre-market validation and ongoing surveillance of AI systems for bias. Responsible AI in healthcare demands that developers and deployers move beyond simplistic proxies that can inadvertently embed societal discrimination. Consider the approach taken by companies building truly clinically validated AI solutions. For instance, a leading cardiac Remote Patient Monitoring (RPM) platform like Hello Heart builds its AI on trusted medical guidelines and clinician expertise. While it leverages objective physiological measurements like blood pressure readings, heart rate, and medication adherence data for personalized guidance, it explicitly states it does not use individual member data to train its underlying AI models, thereby avoiding reliance on historical cost data. This direct, clinically-driven data approach ensures that care recommendations are based on actual patient needs, fostering health equity rather than undermining it.

The Regulatory and Investment Imperative for Algorithmic Fairness

The Optum case vividly illustrates that algorithmic bias is not merely a theoretical concern but a quantifiable risk with significant implications for patient outcomes, public trust, and ultimately, the commercial viability and regulatory standing of AI solutions. For Investors and VCs, understanding and mitigating such risks is paramount. An AI solution with documented algorithmic bias carries substantial regulatory debt and reputational risk, potentially leading to costly remediation, legal challenges, and erosion of market share. The FDA’s SaMD Framework, which continues to evolve with recent updates such as the January 2026 Clinical Decision Support Software Guidance and the August 2025 final guidance on Predetermined Change Control Plans (PCCPs) for AI/ML, increasingly emphasizes the need for algorithmic transparency, fairness, and continuous monitoring for drift and bias FDA guidance on AI/ML in medical devices. Similarly, the FTC’s focus on Algorithmic Fairness, highlighted by its July 2026 proposed policy statement addressing AI accuracy and ideological manipulation of AI outputs, signals a growing regulatory scrutiny over how AI systems impact consumers, including patients FTC guidance on algorithmic discrimination. The economic impact of such discriminatory algorithms extends beyond immediate investment returns. When 200 million lives are potentially impacted by biased care recommendations, the societal cost in terms of preventable illness, reduced productivity, and increased healthcare burden is immense. This underscores the need for robust post-market surveillance mechanisms and a commitment to health equity outcomes from the outset of AI development. Companies that proactively address algorithmic fairness, integrate GMLP (Good Machine Learning Practice) principles, and conduct thorough bias audits will be better positioned for long-term success and regulatory approval. The takeaway is clear: while AI holds transformative potential for healthcare, its responsible deployment requires an unwavering commitment to identifying and eradicating bias. The incident involving Optum’s algorithm serves as a powerful, documented failure that compels us to demand clinically validated, ethically designed AI that truly serves all patients, rather than perpetuating historical injustices. The future of AI in health depends on our collective vigilance and insistence on fairness as a foundational principle.